sector medic suppli devic
messag turn solid overal strength mitg rtg
off-set weak cvg diabet latter two segment like remain
pressur near-term result sluggish guidanc organ
revenu growth expect like backend load
pipelin begin come focu next month
program start impact meantim trend
growth tap continu see share fairli valu current level
rais adjust ep estim yoy
previous midpoint manag revis guidanc rang
model call total revenu organ slightli
prior estim expect cvg growth remain
headwind weigh busi like repeat guidanc
three oper segment appear somewhat conserv howev particularli given
strength exhibit mitg rtg thu far model segment
cc cc respect vs manag outlook meanwhil forecast
diabet sale cc vs guidanc flat revenu combin impli cc
top line growth overal close year
expect sluggish growth persist first half mani
headwind impact today like remain place full year
model call ep yoy total revenu
organ compar prior forecast respect expect
backend load year top line growth improv roughli first half
closer ep growth ramp sequenti well importantli cfo
karen parkhil said compani look way off-set tax headwind
manag also unwil skimp need invest deploy capit
aggress increas share buyback prop near-term earn
correct mindset view albeit one like limit potenti upsid number
underwhelm outlook tap expect focu investor
attent much possibl long-term pipelin manag hint
strategi call teas upcom demo robot surgeri platform
continu see pipelin stori near-term driver
howev robot high profil launch like micra av much need
refresh compani db implant cardiac monitor product line unlik
move needl much longer term continu see
grower top bottom line respect outlook slightli
large-cap med-tech group averag roughli multipl gap
peer widen modestli late ntm ep vs
view valuat fair current level given near-term outlook busi
maintain neutral rate
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag includ lead way healthcar landscap shift fee-for-
valu model re-envis mean centuri
devic compani pursu goal deliv econom valu uniqu
combin technolog servic go far beyond tradit purview
med-tech effort mix success date think concept
valu healthcar stay expect fee-for-valu transit play
meantim see execut around compani core financi target
primari driver valu creation front think manag revis
lrp set much achiev bar one could even allow compani deliv
upsid street expect time pipelin matur near-term howev
see stock fairli valu given growth trajectori
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
respect view valuat appropri given medtron
project long-term growth profil top bottom
line respect lag behind broader sector averag
better opportun elsewher group view assign medtron neutral
upsid risk rate includ revenu growth exce forecast better-
than-expect execut margin target faster expect shift fee-for-
valu healthcar paradigm benefit compani superior scale play
medtron strength prove disrupt competitor
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
